✦ LIBER ✦

Healthcare costs of newly-diagnosed versus existing osteoarthritis patients

✍ Scribed by L. Montejano; T. Le; Z. Cao; Y. Zhao; D. Ang

Book ID: 118477140
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 33 KB
Volume: 12
Category: Article
ISSN: 1528-8447
DOI: 10.1016/j.jpain.2011.02.076

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Estimating Costs of Care for Patients wi

Estimating Costs of Care for Patients with Newly Diagnosed Metastatic Colorectal Cancer

✍ L. Clark Paramore; Simu K. Thomas; Kevin B. Knopf; Lael S. Cragin; Kathy H. Frae 📂 Article 📅 2006 🏛 CIG Media Group, LP. 🌐 English ⚖ 171 KB

Early versus late remission in a cohort

Early versus late remission in a cohort of patients with newly diagnosed epilepsy

✍ Alessandra Del Felice; Ettore Beghi; Giovanni Boero; Angela La Neve; Graziella B 📂 Article 📅 2010 🏛 Wiley (Blackwell Publishing) 🌐 English ⚖ 133 KB

Comparison of Health Care Use and Costs

Comparison of Health Care Use and Costs in Newly Diagnosed and Established Patients With Fibromyalgia

✍ Leigh Ann White; Rebecca L. Robinson; Andrew P. Yu; Anna Kaltenboeck; Seth Samue 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 118 KB

Cost-effectiveness analysis of top-down

Cost-effectiveness analysis of top-down versus step-up strategies in patients with newly diagnosed active luminal Crohn’s disease

✍ Marchetti, Monia; Liberato, Nicola L.; Sabatino, Antonio; Corazza, Gino R. 📂 Article 📅 2012 🏛 Springer 🌐 French ⚖ 341 KB

PRS8: TREATMENT AND ASSOCIATED COSTS OF

PRS8: TREATMENT AND ASSOCIATED COSTS OF NEWLY DIAGNOSED COPD PATIENTS IN A MANAGED CARE POPULATION

✍ F Cox; K Ramaswamy; L Okamoto; T McLaughlin 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB

Cost-effectiveness of imatinib versus in

Cost-effectiveness of imatinib versus interferon-α plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia

✍ Shelby D. Reed; Kevin J. Anstrom; Jennifer A. Ludmer; G. Alastair Glendenning; K 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 119 KB 👁 1 views

## Abstract ## BACKGROUND Despite a lack of long‐term data, imatinib has become standard therapy for patients with newly diagnosed chronic‐phase chronic myeloid leukemia (CML) who are not candidates for allogeneic stem cell transplantation. In the current study, the authors estimated the increment